Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
134.89
-2.17 (-1.58%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,111,271
Open
135.40
Bid (Size)
134.99 (1)
Ask (Size)
135.39 (3)
Prev. Close
137.06
Today's Range
134.66 - 135.67
52wk Range
86.96 - 148.15
Shares Outstanding
N/A
Dividend Yield
1.31%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
August 16, 2024
Medicare patients struggle to access Novo Nordisk's Wegovy for heart disease treatment despite new guidelines, with many plans still denying coverage, highlighting challenges in the U.S. healthcare...
Via
Benzinga
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
August 16, 2024
Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron, is projected to generate up to $14 billion annually by 2032, while...
Via
Benzinga
Performance
YTD
+32.10%
+32.10%
1 Month
-0.39%
-0.39%
3 Month
+2.27%
+2.27%
6 Month
+8.77%
+8.77%
1 Year
+46.05%
+46.05%
More News
Read More
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
August 16, 2024
Via
The Motley Fool
Unpacking the Latest Options Trading Trends in Novo Nordisk
August 15, 2024
Via
Benzinga
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
August 15, 2024
Via
The Motley Fool
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
August 15, 2024
Via
Investor's Business Daily
Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors?
August 15, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
August 14, 2024
Via
Benzinga
Exposures
Product Safety
Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters
August 14, 2024
Via
Benzinga
3 Stable Blue-Chip Stocks to Buy for the Market Storm
August 14, 2024
Via
InvestorPlace
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
August 14, 2024
Via
The Motley Fool
Being Vain Has Its Benefits. Why Eli Lilly And The 'Me-Conomy' Are Here To Stay.
August 13, 2024
Via
Investor's Business Daily
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
August 13, 2024
Via
InvestorPlace
Novo Nordisk Just Hit 3 Snags in a Row. Is Its Stock Still a Buy?
August 13, 2024
Via
The Motley Fool
This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock
August 13, 2024
Via
The Motley Fool
Weight Loss Drugs Like Ozempic, Zepbound May Reduce Cancer Risks, Studies Suggest
August 12, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 12, 2024
Via
Benzinga
Weight Loss Stocks Could Become Alzheimer's Drugs Stocks. Here's Why That's Bullish for Novo Nordisk
August 12, 2024
Via
The Motley Fool
MarketBeat Week in Review – 8/5 - 8/9
August 10, 2024
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug
August 09, 2024
Via
Benzinga
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
August 09, 2024
Via
Investor's Business Daily
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
August 09, 2024
Via
MarketBeat
Topics
ETFs
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
August 09, 2024
Via
The Motley Fool
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
August 09, 2024
Via
MarketBeat
Novo Nordisk's Growth Opportunities Go Far Beyond Just Weight Loss and Diabetes
August 08, 2024
Via
The Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.